Significant progress is underway in pinpointing treatments and speeding up diagnosis of rare disease, thanks to digital trials and data-driven commercial strategy.
The use of artificial intelligence (AI) in the biopharma industry has the potential to revolutionise drug discovery and development, as well as improve patient care.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough